CSL Biotherapies starts shipment of seasonal influenza vaccine for 2013-2014 season

Editorial Checklist Reviewed
CSL Biotherapies, Inc.Aug 7 2013NewsGuard 100/100 Score

CSL Biotherapies, Inc. announced today that shipment of its seasonal influenza vaccine for the 2013-2014 season has started.

"Given the magnitude of influenza burden in the U.S. and the unpredictability of seasonal outbreaks, timely delivery of flu vaccines is more critical now than ever before," said Dr. Marie Mazur, Head of Worldwide Commercial Operations, Influenza. "CSL Biotherapies is committed to addressing this public health need by consistently delivering its influenza vaccine early to the healthcare providers in the United States."

CSL Biotherapies will ship approximately 10 million doses of the seasonal flu vaccine to the United States for the upcoming season. Shipment will comprise multi-dose and pre-filled syringe presentations.

Source:

CSL Biotherapies, Inc.

Posted in: Disease/Infection News | Pharmaceutical News

Tags: , , , ,

Comments (0)

Suggested Reading

Wastewater surveillance detects influenza and H5 viruses from human and animal sources
Cognitive distortions and deliberate ignorance lead to COVID-19 vaccine refusal, study says
Collaborative study offers hope for syphilis vaccine development
Single dose of MVA-BN vaccine offers 58% protection against mpox
New vaccine candidate shows promise for protecting against Lassa fever
Evolution of vaccine adjuvants from empirical discovery to rational design
Phase 1 trial shows safety and efficacy of personalized vaccine for lymphoplasmacytic lymphoma
Nearly half of people older adults plan to get the updated COVID-19 vaccine, poll suggests

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Single dose of MVA-BN vaccine shows 58% effectiveness against mpox